60 Degrees Pharmaceuticals updates tafenoquine babesiosis data in Oct. 23 8-K presentationOct 23People60 Degrees Pharmaceuticals LLCtafenoquine
60 Degrees updates investors on tafenoquine babesiosis program ahead of January 2027 readoutOct 6Clinical readout60 Degrees Pharmaceuticals LLCtafenoquine
60 Degrees Pharmaceuticals seeks FDA priority voucher for babesiosis drugSep 14Regulatory decision60 Degrees Pharmaceuticals LLCtafenoquine
60 Degrees Pharmaceuticals prices $1.0 million private placementAug 4Financing60 Degrees Pharmaceuticals LLC